RecruitingPhase 2NCT07133750

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

A Phase II, Multicenter, Open Label, Parallel Cohort Clinical Trial to Evaluate the Efficacy and Safety of PM8002 (BNT327) in Combination With Chemotherapy in First Line MSS or MSI-L/pMMR Metastatic Colorectal Cancer

Sponsor

Biotheus Inc.

Enrollment

100 participants

Start Date

Aug 19, 2025

Study Type

INTERVENTIONAL

Conditions

CRC (Colorectal Cancer)

Summary

PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Chemotherapy Regimen 1, a drug called Chemotherapy Regimen 2, and others for people with crc (colorectal cancer). The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPM8002

IV infusion

DRUGChemotherapy Regimen 1

IV infusion

DRUGChemotherapy Regimen 2

Oral administration and IV infusion

DRUGChemotherapy Regimen 3

IV infusion

Locations(11)

Peking University First Hospital

Beijing, Beijing Municipality, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Hubei Cancer Hospital

Wuhan, Hubei, China

Jilin Cancer Hospital

Changchun, Jilin, China

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, China

Sichuan Cancer Hospital

Chengdu, Sichuan, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07133750

Related Trials

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849255 locations

Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC

NCT072248411 location

cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

NCT072248151 location

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

NCT0683556912 locations

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

NCT0691707917 locations